Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Akebia Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 79 | 76 | −3 |
| Shares | 50.3M | 50.9M | +564.8K (+1.1%) |
| Value | $46.0M | $58.0M | +$12.0M (+26.0%) |
New holders (7)
Institutions that held Akebia Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Creative Planning | 110,428 | $125.9K | 0.00% |
| Verition Fund Management LLC | 55,870 | $63.7K | 0.00% |
| Willis Johnson & Associates, Inc. | 17,500 | $19.9K | 0.00% |
| Private Advisor Group, LLC | 16,141 | $18.4K | 0.00% |
| Baird Financial Group, Inc. | 12,743 | $14.5K | 0.00% |
| Johnson Financial Group, Inc. | 1,400 | $1.60K | 0.00% |
| NBC Securities, Inc. | 690 | $0 | 0.00% |
Sold out (10)
Institutions that held Akebia Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Virtu Financial LLC | 50,633 | $46.0K |
| Advisory Services Network, LLC | 27,000 | $24.7K |
| Graham Capital Management, L.P. | 26,586 | $24.3K |
| Wolverine Trading, LLC | 20,198 | $18.7K |
| Goldman Sachs Group Inc | 18,273 | $16.7K |
| GTS Securities LLC | 17,549 | $16.1K |
| Visionary Wealth Advisors | 14,819 | $13.6K |
| First Horizon Advisors, Inc. | 5,600 | $5.12K |
| Citadel Advisors LLC | 965 | $883 |
| Royal Bank of Canada | 500 | $0 |